BioSpace News Archive

Seagen Inc. announced promising efficacy and safety results from Part B of an open-label, phase 2 clinical trial evaluating ADCETRIS® in a novel combination with nivolumab, doxorubicin, and dacarbazine as a frontline treatment for patients with advanced stage classical Hodgkin lymphoma.

Antengene Corporation Limited announced a clinical trial collaboration to evaluate the safety, pharmacokinetics and preliminary efficacy of ATG-017 in combination with Bristol Myers Squibb’s PD-1 checkpoint inhibitor, Opdivo®.

Avenue Therapeutics, Inc., a company focused on the development of intravenous tramadol for the U.S. market, announced the pricing of an underwritten public offering with gross proceeds to the Company expected to be approximately $2.0 million, before deducting underwriting discounts and commissions and other estimated expenses payable by the Company.

Pfizer Inc. and Sangamo Therapeutics, Inc., a genomic medicines company, announced updated follow-up data from the Phase 1/2 Alta study of giroctocogene fitelparvovec, an investigational gene therapy for patients with moderately severe to severe hemophilia A.

bluebird bio, Inc. announced updated results from its Phase 1/2 HGB-206 study of lovotibeglogene autotemcel gene therapy for sickle cell disease, including further analyses from its pivotal cohort, HGB-206 Group C, following enhancements to the manufacturing protocols and treatment process.

BeiGene announced results from a planned interim analysis of the Phase 3 SEQUOIA trial in patients with treatment-naïve chronic lymphocytic leukemia, including the randomized Cohort 1 comparing BRUKINSA to bendamustine plus rituximab and Cohort 3 of BRUKINSA in combination with venetoclax in patients with deletion of chromosome 17p and/or pathogenic TP53 variants.

StemiRNA, a leader in research and development of mRNA therapeutics, welcomes Dr. Jack Hu as Chief Financial Officer.

Ascentage Pharma announced that the Phase II pivotal study of the company’s novel Bcl-2 selective inhibitor, lisaftoclax, for the treatment of relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma has been approved by the Center for Drug Evaluation in China.

IASO Biotherapeutics and Innovent Biologics, Inc. jointly announced the latest data from the phase 1/2 clinical study of a fully human B-cell maturation antigen chimeric antigen receptor T-cell therapy in an oral presentation at the 63rd American Society of Hematology Annual Meeting.

The Janssen Pharmaceutical Companies of Johnson & Johnson announced longer-term results from the Phase 1b/2 CARTITUDE-1 study evaluating the efficacy and safety of ciltacabtagene autoleucel, an investigational B-cell maturation antigen -directed chimeric antigen receptor T-cell therapy administered as a single infusion, in the treatment of patients with relapsed and/or refractory multiple myeloma.